The Agile Drug Discovery Company
Synfini will dramatically reduce the time and cost of modern molecular discovery by uniting physical and virtual chemistry through expert-curated AI and discovery-focused robotic automation, leading to the most dynamic synthesis data and designer molecules.
Our mission is dramatically reduce the time and cost of translating targets, hits and virtual drug concepts to validated candidates, which will enable our partners to create over a thousand new drug candidates over the next ten years.
Streamlining Drug Discovery by Uniting Physical and Virtual Chemistry
The proliferation of drug targets and the explosion of virtual drug hits hypothesized by computational chemistry and generative AI has intensified the demand for physical
synthesis and testing of new molecules. Traditional methods are costly and time-
consuming, creating a bottleneck in the development of new therapeutics.
Synfini unites the virtual and physical with a powerful Agile AI Foundry for drug discovery, leveraging a unique combination of chemist-first AI and chemistry robotic automation to rapidly and cost effectively generate robust data to validate new drug designs.
This modern approach to medicinal chemistry helps biologists and chemists speed up lead optimization, improve predictive accuracy, and explore a wider range of chemical possibilities—making drug discovery faster and more collaborative.
Press Releases
